• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

No benefit with hydroxychloroquine (Plaquenil) over placebo in Sjogren’s Syndrome [JOQUER Trial]

byJeffrey CohenandPriyanka Vedak
July 15, 2014
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. After 24 weeks of treatment, hydroxychloroquine was no more effective than placebo in improving scores for dryness, pain, and fatigue in Sjogren’s Syndrome.

Evidence Rating Level: 2 (Good)

Study Rundown: Sjogren’s Syndrome (SS) is an autoimmune disease that results in dry eyes, dry mouth, joint and muscle pain, and less commonly, systemic complications.  Hydroxychloroquine, an immunomodulatory medication, is frequently used to treat SS, however the evidence supporting its efficacy is inconsistent. This study (the JOQUER Trial) is the first randomized contolled trial to assess this issue. 120 individuals with SS were randomized to receive hydroxychloroquine or placebo for 24 weeks and measured the proportion of participants in each group with at least a 30% reduction in dryness, fatigue, and pain. Following the first 24 weeks of the study, all participants received hydroxychloroquine between weeks 24 to 48.There was no significant difference between the two groups at either the 24 or 48-week point.

This study demonstrates the limited efficacy of hydroxychloroquine in treating primary Sjogren’s Syndrome and may consequently affect the treatment choices pursued by clinicians for this disease. As prior studies examining this issue utilized less robust study designs, one strength of this study is its double blind, randomized, placebo-controlled methodology.  Weaknesses of the study include the use of only three domains as outcomes, permitting participants to continue other medications, and the relatively small sample size and follow up times.  Despite the fact that this study did not demonstrate efficacy of hydroxychloroquine use for primary SS, a larger and longer study may be warranted to assess for the potential long-term utility of this treatment in SS.

Click to read the study, published today in JAMA

Relevant Reading: Treatment of primary Sjögren syndrome: a systematic review

In-Depth [randomized controlled trial]: This study randomized 120 individuals with SS to receive hydroxychloroquine or placebo for 24 weeks and measured their numeric analog scales on three domains: dryness, fatigue, and pain.  The proportions of individuals in each group with at least a 30% reduction in at least 2 of 3 domains were compared.  The second phase of the study involved treating all participants with hydroxychloroquine between weeks 24-48.  At the conclusion of the first 24 weeks, 17.9% of individuals in the hydroxychloroquine group and 17.2% of participants in the placebo group had at least a 30% reduction in two of the three measured domains (OR 1.01, 95% CI 0.37-2.78, p=0.98). At week 48, 30.4% of those in the hydroxychloroquine group and 18.8% of those in the placebo group had at least a 30% reduction in at least 2 of 3 domains (OR 2.06, 95% CI 0.66-6.43, p=0.21).

RELATED REPORTS

Low-dose interleukin 2 may be beneficial for primary Sjögren syndrome

#VisualAbstract: Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome without serious adverse events

Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome

More from this author: Ambulances equipped for thrombolysis allow for more rapid stroke treatment, Bariatric weight loss surgery linked with remission in diabetics, No link between TNF-a inhibitor use and cancer in inflammatory bowel disease, Stem cell transplant may be effective in sickle cell disease, Varenicline (Chantix) with nicotine patches effective in smoking cessation 

Image: CC/Wiki

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: hydroxychloroquine (Plaquenil)Sjögren’s Syndrome
Previous Post

Diets rich in omega fatty acids may reduce ALS (Lou Gehrig’s) risk

Next Post

Population-based risk factors and geographical trends identified for vitiligo

RelatedReports

Chronic Disease

Low-dose interleukin 2 may be beneficial for primary Sjögren syndrome

December 13, 2022
#VisualAbstract: Convalescent plasma is not effective at improving clinical outcomes or reducing mortality of COVID-19 patients not on mechanical ventilation
StudyGraphics

#VisualAbstract: Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome without serious adverse events

February 3, 2022
Autoantibodies may precede symptom onset in Sjögren’s Syndrome
Chronic Disease

Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome

January 26, 2022
#VisualAbstract: Hydroxychloroquine with/without azithromycin for mild to moderate SARS-CoV-2
StudyGraphics

#VisualAbstract: Hydroxychloroquine with/without azithromycin for mild to moderate SARS-CoV-2

August 11, 2020
Next Post
Population-based risk factors and geographical trends identified for vitiligo

Population-based risk factors and geographical trends identified for vitiligo

Antidepressant may reduce mental stress-induced myocardial ischemia (REMIT Trial)

Decreased facial expression variability linked with serious cardiac disease

No obesity paradox found between BMI, stroke, and death

Stroke within past 9 months linked with adverse surgical outcomes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options